ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Darinaparsin manuscript.pdf (1006 kB)

In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA dependent RNA polymerase (RdRp) and Necessary Proteases

preprint
submitted on 27.04.2020, 15:49 and posted on 28.04.2020, 11:11 by Trinath Chowdhury, Gourisankar Roymahapatra, Santi M Mandal
The work demonstrate screening of several arsenical compounds against RdRp of coronavirus. The study implies out of all arsenical compounds, darinaparsin shows its most effective results based on in silico docking analysis. This study also confirmed the significant interaction between the active site of viral replicase protein, endoribonuclease protein and different proteases with darinaparsin.

History

Email Address of Submitting Author

tri.baps@gmail.com

Institution

Indian Institute of Technology Kharagpur

Country

India

ORCID For Submitting Author

0000-0003-2922-326X

Declaration of Conflict of Interest

There is no conflct of interest between the authors.

Exports

ChemRxiv

Exports